Bank of New York Mellon’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-136,746
| Closed | -$231K | – | 4295 |
|
|
2026
Q1 | $231K | Buy |
136,746
+20,980
| +18% | +$91.9K | ﹤0.01% | 3952 |
|
|
2025
Q4 | $600K | Sell |
115,766
-6,086
| -5% | -$31.3K | ﹤0.01% | 3505 |
|
|
2025
Q3 | $636K | Buy |
121,852
+10,511
| +9% | +$54.8K | ﹤0.01% | 3461 |
|
|
2025
Q2 | $426K | Buy |
111,341
+410
| +0.4% | +$1.06K | ﹤0.01% | 3595 |
|
|
2025
Q1 | $638K | Sell |
110,931
-5,847
| -5% | -$34.6K | ﹤0.01% | 3326 |
|
|
2024
Q4 | $583K | Sell |
116,778
-1,308
| -1% | -$6.71K | ﹤0.01% | 3442 |
|
|
2024
Q3 | $636K | Sell |
118,086
-77,636
| -40% | -$370K | ﹤0.01% | 3377 |
|
|
2024
Q2 | $648K | Buy |
195,722
+34,885
| +22% | +$137K | ﹤0.01% | 3434 |
|
|
2024
Q1 | $526K | Sell |
160,837
-9,202
| -5% | -$30.3K | ﹤0.01% | 3498 |
|
|
2023
Q4 | $597K | Sell |
170,039
-7,324
| -4% | -$22.6K | ﹤0.01% | 3460 |
|
|
2023
Q3 | $1.18M | Sell |
177,363
-234
| -0.1% | -$1.74K | ﹤0.01% | 3062 |
|
|
2023
Q2 | $1.49M | Buy |
177,597
+111,294
| +168% | +$1.1M | ﹤0.01% | 2991 |
|
|
2023
Q1 | $658K | Buy |
66,303
+263
| +0.4% | +$1.86K | ﹤0.01% | 3343 |
|
|
2022
Q4 | $460K | Sell |
66,040
-182
| -0.3% | -$1.04K | ﹤0.01% | 3577 |
|
|
2022
Q3 | $354K | Sell |
66,222
-12,253
| -16% | -$73.5K | ﹤0.01% | 3754 |
|
|
2022
Q2 | $314K | Sell |
78,475
-131,340
| -63% | -$452K | ﹤0.01% | 3852 |
|
|
2022
Q1 | $932K | Buy |
209,815
+22,748
| +12% | +$90.6K | ﹤0.01% | 3360 |
|
|
2021
Q4 | $749K | Buy |
187,067
+3,258
| +2% | +$24.8K | ﹤0.01% | 3556 |
|
|
2021
Q3 | $1.61M | Sell |
183,809
-38,192
| -17% | -$351K | ﹤0.01% | 3120 |
|
|
2021
Q2 | $2.52M | Buy |
222,001
+174,647
| +369% | +$2.1M | ﹤0.01% | 2850 |
|
|
2021
Q1 | $563K | Sell |
47,354
-9,320
| -16% | -$107K | ﹤0.01% | 3621 |
|
|
2020
Q4 | $388K | Buy |
56,674
+41,126
| +265% | +$289K | ﹤0.01% | 3733 |
|
|
2020
Q3 | $115K | Hold |
15,548
| – | – | ﹤0.01% | 3937 |
|
|
2020
Q2 | $65K | Sell |
15,548
-51,246
| -77% | -$187K | ﹤0.01% | 3950 |
|
|
2020
Q1 | $165K | Sell |
66,794
-7,463
| -10% | -$33.6K | ﹤0.01% | 3792 |
|
|
2019
Q4 | $431K | Sell |
74,257
-3,290
| -4% | -$19K | ﹤0.01% | 3662 |
|
|
2019
Q3 | $409K | Buy |
77,547
+2,194
| +3% | +$11.8K | ﹤0.01% | 3651 |
|
|
2019
Q2 | $452K | Buy |
75,353
+5,406
| +8% | +$40.7K | ﹤0.01% | 3651 |
|
|
2019
Q1 | $631K | Sell |
69,947
-69,358
| -50% | -$589K | ﹤0.01% | 3435 |
|
|
2018
Q4 | $1.16M | Buy |
139,305
+9,290
| +7% | +$95.2K | ﹤0.01% | 3024 |
|
|
2018
Q3 | $1.79M | Buy |
130,015
+80,173
| +161% | +$650K | ﹤0.01% | 2905 |
|
|
2018
Q2 | $396K | Buy |
49,842
+29,051
| +140% | +$232K | ﹤0.01% | 3731 |
|
|
2018
Q1 | $156K | Buy |
20,791
+2,413
| +13% | +$18.3K | ﹤0.01% | 3978 |
|
|
2017
Q4 | $125K | Sell |
18,378
-192
| -1% | -$1.26K | ﹤0.01% | 4037 |
|
|
2017
Q3 | $134K | Buy |
+18,570
| New | +$97K | ﹤0.01% | 3949 |
|
Other funds holding ALDX
AAP
GCP
WC
CPIG
QC
IAIM
Bank of New York Mellon's ALDX Position: Q2 2026 in Review
Bank of New York Mellon sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 136,746 shares — an estimated $231K sold.
Bank of New York Mellon first reported a position in ALDX in Q3 2017 and held it in 35 quarters. The position peaked at $2.52M in Q2 2021. 35 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.
- Bank of New York Mellon reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
- Bank of New York Mellon sold 136,746 Aldeyra Therapeutics shares in Q2 2026, an estimated $231K.
- Bank of New York Mellon first reported a position in Aldeyra Therapeutics in Q3 2017 and held it in 35 quarters.
- Bank of New York Mellon's Aldeyra Therapeutics position peaked at $2.52M in Q2 2021.
- 35 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.